Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunobinop - Imbrium Therapeutics/Shionogi

Drug Profile

Sunobinop - Imbrium Therapeutics/Shionogi

Alternative Names: IMB-115; IMB-115 tosylate; IT-1315; RSC117957; S-117957; Sunobinop tosylate; V-117957

Latest Information Update: 15 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma; Shionogi
  • Developer Imbrium Therapeutics; Purdue Pharma; Shionogi
  • Class Analgesics; Aza compounds; Carboxylic acids; Quinoxalines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insomnia
  • Phase I Interstitial cystitis; Overactive bladder
  • Preclinical Fibromyalgia
  • Discontinued Dental pain; Neuropathic pain

Most Recent Events

  • 15 Mar 2022 Phase-I clinical trials in Interstitial cystitis in USA (PO) (Imbrium Therapeutics pipeline, March 2022)
  • 15 Mar 2022 Phase-I clinical trials in Overactive bladder in USA (PO) (Imbrium Therapeutics pipeline, March 2022)
  • 06 Nov 2020 Imbrium Therapeutics completes a phase II trial in Insomnia in USA (PO) (NCT04035200)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top